Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Microsoft — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $280.01 (market cap $39.89B), while Microsoft trades at $385.22 (market cap $2.86T). The key difference: Microsoft is far larger — about 71.7× Alnylam Pharmaceuticals, Inc.'s market cap, and Microsoft pays a 0.95% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MSFT | |
|---|---|---|
Market Cap | $39.89B | $2.86T |
Sector | Health | Technology |
52-Week High | $491.22 | $542.07 |
52-Week Low | $278.09 | $352.83 |
Enterprise Value | $38.15B | $2.84T |
Volume | — | 36,654,621 |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Microsoft (MSFT) trades at $387.89, up 0.72% today, with a bearish technical signal despite strong fundamentals. The stock has consistently beaten earnings estimates, including Q1 2026 EPS of $4.27 vs. $4.06 expected. Revenue grew to $281.72B in 2025, with a net income margin of 39.34%. Analyst consensus is strongly bullish with an $548.87 price target, though technical indicators show resistance near $388.
Outlook remains positive driven by AI leadership and cloud growth, but risks include high capital expenditure concerns and competitive pressures. The stock offers long-term value with robust cash flow and dividend payments, though near-term volatility may persist due to macroeconomic and geopolitical factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
